Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous v3.4.2 in the revision history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedResults section updated with data on dose-limiting toxicities, timing, and RECIST responses. Exploratory biomarker endpoints were removed.SummaryDifference3%

- Check34 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1 along with the funding/operating-status notice. There are no visible changes to the study details or results.SummaryDifference0.5%

- Check42 days agoChange DetectedAdministrative notices were added: a government funding lapse notice and an update to version 3.4.1. The prior version 3.4.0 was removed.SummaryDifference0.5%

- Check48 days agoChange DetectedAdded a glossary toggle and updated footer/version details to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0. Removed older wording/capitalization variants ('Last Update Submitted that met QC Criteria', 'No FEAR Act data') and the previous revision label (v3.3.4).SummaryDifference0.2%

- Check63 days agoChange DetectedRevision: v3.3.4 replaces the previous Revision: v3.3.3 on the page header/footer. This appears to be a minor system update and does not affect trial details.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.